Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481123 | 0.78 | MEN1 (0.30) | ALDH1A1MEN1KMT2A | |
| SCHEMBL19075642 | 0.74 | MEN1 (0.30) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14343401 | 0.70 | HSD11B1 (0.43) | MEN1KMT2AHSD11B1EPHX2 | |
| SCHEMBL18116222 | 0.70 | HSD11B1 (0.43) | MEN1KMT2AHSD11B1EPHX2 | |
| SCHEMBL22474748 | 0.64 | CHRNB2 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL22474758 | 0.63 | ALDH1A1 (0.36) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL20937472 | 0.62 | ALDH1A1 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL26983251 | 0.61 | MEN1 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL11279036 | 0.59 | OPRM1 (0.34) | ALDH1A1 | |
| SCHEMBL31674212 | 0.59 | MEN1 (0.31) | ALDH1A1MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CHRNB2 3513/4885CHRNA3 2138/4885CHRNA4 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.